FDA Approves Generic Antiretroviral Drug Combination, Allowing PEPFAR to Purchase Drugs for Use in Developing Countries
January 26, 2005
FDA on Tuesday announced that it has approved a generic version of a "widely used" co-packaged antiretroviral drug regimen, a move that is "expected to expand AIDS treatment in the developing world" by allowing the President's Emergency Plan for AIDS Relief to purchase the drugs, the AP/Yahoo! News reports. The approval of the regimen, which is made by South Africa's Aspen Pharmacare, is the first time FDA has approved a generic HIV/AIDS drug manufactured by a foreign pharmaceutical company. The regimen includes a generic version of GlaxoSmithKline's fixed-dose combination Combivir, which contains the antiretroviral drugs lamivudine and zidovudine, and a version of Boehringer Ingelheim's Viramune, known generically as nevirapine, which Aspen packages together. Although FDA in December 2004 approved a generic antiretroviral made by Woodcliff, N.J.-based Barr Laboratories, its approval of Aspen's generics is seen as a "major advancement" because the combination is "so widely used as a first-line therapy," according to the AP/Yahoo! News (Agovino, AP/Yahoo! News, 1/26). Aspen completed its marketing application on Jan. 13, and FDA completed its expedited review within two weeks because the co-packaged regimen has "great public health significance," according to FDA Acting Commissioner Lester Crawford (FDA release, 1/25). The Bush administration also waived the $500,000 application fee under its new FDA fast-track review program announced in May 2004 (McNeil, New York Times, 1/26). According to Mark Isaac, vice president of the Elizabeth Glaser Pediatric AIDS Foundation, the estimated cost of the regimen could be between $20 and $30 per person per month. He added that the foundation currently pays $55 per person per month for the brand-name drugs included in the regimen.
However, the "praise for the FDA action was not unanimous," according to the Post. Medecins Sans Frontieres "questioned the need" for FDA approval because the regimen already has been "widely endorsed" by some international health groups, the Post reports. "It sends a strange signal that the FDA should be the arbiter of drug safety for African governments," Rachel Cohen, U.S. director of MSF's Campaign for Access to Essential Medicines, said, adding that the United States should support the World Health Organization's certification program. "We should not have to go down this road to begin with. It is a curious time for FDA to be boasting about its ability to monitor drug safety given recent scandals around Vioxx and other products," Cohen said (Washington Post, 1/26). "Confusion has been sown and precious resources wasted as the administration unnecessarily insisted on brand-name drugs," Paul Zeitz, executive director of the Global AIDS Alliance, said. "This approval, a full two years after the president's declaration of a global AIDS emergency, is a positive development. But, the product that was approved is not a fixed-dose combination, and, as a result, is not as easy to take. Also, the company would not have gotten its drug approved without cozy relationships with several brand-name companies, something not all producers of essential, generic medications enjoy. As a result, this might not be replicated any time soon" (GAA release, 1/26).
President Bush Ahead of Congressional Black Caucus Meeting Tells Black Leaders That Fighting HIV/AIDS in Africa Still a Priority
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.